PRL3 & Tumor Metastasis
Tumor Metastasis: Metastasis is the leading cause of death in cancer. Primary tumors can usually be surgically removed, and if diagnosed and treated early, high cure rates can be achieved. Unfortunately, metastasis is usually not detected until later disease stages because reliable early-stage detection markers and treatment options for metastasis simply do not exist.
Attogen Biomedical Research has the first and only monoclonal antibody with specificity to a recently discovered, well validated tumor metastasis promoting target PRL-3. This antibody has demonstrated strong promise as a diagnostic biomarker and drug discovery tool for the early detection, prevention and treatment of tumor metastasis and micro-metastasis. This represents an extraordinary opportunity to consider metastasis as a disease condition separate from a primary cancer diagnosis.
Attogen Biomedical Research provides these antibody reagents to promote scientific advancement in the field of tumor metastasis and tumor stem cell research.
(Patent Pending - Monoclonal antibodies to PRL3 for utilities in diagnostics and therapeutics.)
Published Literature on PRL-3:
38. Wang H, et al., 2007, Cancer Res. 2007 Apr 1;67(7):2922-6
PRL-3 Down-regulates PTEN Expression and Signals through PI3K to Promote Epithelial-Mesenchymal Transition.
37. Liang F, et al., 2007, J Biol Chem. 282(8):5413-9.
PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
36. Miskad UA, et al., 2007, Virchows Arch. ;450(3):303-10.
High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study.
35. Radke I, Gotte M, Kersting C, Mattsson B, Kiesel L. Br J Cancer . 2006 2006 Aug 7;95(3):347-54.
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer.
34. Li Z, Zhan W, Wang Z, Zgu B et al., Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37.
Inhibition of PRL-3 gene expression in gastric cancer cell line SGC7901 via microRNA suppressed reduces peritoneal metastasis.
33. Ke Guo, Jie Li, Haihe Wang, Motomi Osato, Jing Ping Tang, Samantha Yiling Quah, Bin Qi Gan, and Qi Zeng. Cancer Res 2006; 66: (19). October 1, 2006
PRL-3 Initiates Tumor Angiogenesis by Recruiting Endothelial Cells In vitro and In vivo
32. Wang L, Peng L, Dong B, et al., Shou C. Ann Oncol. 2006 Jul 27
Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome.
31. Choi SK, Oh HM, Lee SK, Jeong DG, Ryu SE, Son KH, Han DC, Sung ND, Baek NI, Kwon BM. Nat Prod Res. 2006 Apr;20(4):341-6.
Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3).
30. Zhao GP, Zhou ZG, Lei WZ, Yu YY, Zheng XL, Gao HK. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 May;8(3):237-40.
Expression of phosphatase of regenerating liver-3 mRNA and its clinical implications in human colorectal carcinoma.
29. Wallin AR, Svanvik J, Adell G, Sun XF. Int J Radiat Oncol Biol Phys. 2006 Apr 18 [Epub ahead of print]
Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy
28. Dursina B, Reents R, Delon C, Wu Y, Kulharia M, Thutewohl M, Veligodsky A, Kalinin A, Evstifeev V, Ciobanu D, Szedlacsek SE, Waldmann H, Goody RS, Alexandrov K. J Am Chem Soc. 2006 Mar 8;128(9):2822-35
Identification and specificity profiling of protein prenyltransferase inhibitors using new fluorescent phosphoisoprenoids
27. Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, Kang SK, Jeong DG, Jung SK, Lee SH, Kim HM, Park SK, Lee KH, Lee CW, Ryu SE, Choi JK Bioorg Med Chem Lett. 2006 Mar 9
Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors
26. James J. Fiordalisi, Patricia J. Keller, and Adrienne D. Cox. Cancer Res 2006; 66: (6). March 15, 2006
PRL Tyrosine Phosphatases Regulate Rho Family GTPases to Promote Invasion and Motility
25. Peng L, Jin G, Wang L, Guo J, Meng L, Shou C. Biochem Biophys Res Commun. 2006 31;342(1):179-83.
Identification of integrin alpha1 as an interacting protein of protein tyrosine phosphatase PRL-3
24. Rouleau C, Roy A, St Martin T, Teicher BA. Mol cancer Ther. 2006 5(2) 219-29
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and function.
23. Stephens BJ, Han H, Gokhale V, Von Hoff DD. Mol Cancer Ther. 2005 Nov;4(11):1653-61.
PRL phosphatases as potential molecular targets in cancer.
22. Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, Bardelli A, Brogggini M.
Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9.
PRL-3 phosphatase is implicated in ovarian cancer growth.
21. Cuevas IC, Rohloff P, Sanchez DO, Docampo R. Eukaryot Cell. 2005; 4(9):1550-61.
Characterization of farnesylated protein tyrosine phosphatase TcPRL-1 from Trypanosoma cruzi.
20. Li J, Guo K, Koh VW, Tang JP, Gan BQ, Shi H, Li HX, Zeng Q. Clin Cancer Res. 2005 Mar 15;11(6):2195-204.
Generation of PRL-3- and PRL-1-specific monoclonal antibodies as potential diagnostic markers for cancer metastases
19. T.E. Buffart , J. Coffa , M.A.J.A. Hermsen , B. Carvalho , J.R.M. van der Sijp, B. Ylstra, G. Pals, J.P. Schouten, G.A. Meijer. Cellular Oncology 2005; 27:57-65
DNA copy number changes at 8q11-24 in metastasized colorectal cancer
18. Jeong DG, Kim SJ, Kim JH, Son JH, Park MR, Lim SM, Yoon TS, Ryu SE. J Mol Biol. 2005 Jan 14;345(2):401-13.
Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms.
17. Belinda S. Parker, Pedram Argani, Brian P. Cook, Han Liangfeng, Scott D. Chartrand, Mindy Zhang, Saurabh Saha, Alberto Bardelli, Yide Jiang, Thia B. St. Martin, Mariana Nacht, Beverly A. Teicher, Katherine W. Klinger, Saraswati Sukumar, and Stephen L. Madden. CANCER RESEARCH 64, 7857–7866, November 1, 2004.
Alterations in Vascular Gene Expression in Invasive Breast Carcinoma.
16. Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. Clin Cancer Res. 2004 Nov 1;10(21):7318-28.
High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases.
15. Guo K, Li J, Tang JP, Koh V, Gan BQ, Zeng Q. Cancer Biol Ther. 2004 Oct 27;3(10)
Catalytic Domain of PRL-3 Plays an Essential Role in Tumor Metastasis: Formation of PRL-3 Tumors Inside the Blood Vessels.
14. Sager J, Benvenuti S, Bardelli A. Cancer Biol Ther. 2004 Oct 8;3(10)
PRL-3: A Phosphatase for Metastasis?
13. Peng L, Ning J, Meng L, Shou C. J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6.
The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
12. Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, Zhang M, Gao X, Xu Q. Am J Pathol. 2004 Jun;164(6):2039-54.
Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells.
11. Kim KA, Song JS, Jee J, Sheen MR, Lee C, Lee TG, Ro S, Cho JM, Lee W, Yamazaki T, Jeon YH, Cheong C. FEBS Lett. 2004 May 7;565(1-3):181-7.
Structure of human PRL-3, the phosphatase associated with cancer metastasis.
10. Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, Ekiel I. J Biol Chem. 2004 Mar 19;279(12):11882-9.
Structural insights into molecular function of the metastasis-associated phosphatase PRL-3.
9. Peng L, Li Y, Meng L, Shou C. Hybrid Hybridomics. 2004 Feb;23(1):23-7
Preparation and characterization of monoclonal antibody against protein tyrosine phosphatase PRL-3.
8. Miskad UA, Semba S, Kato H, Yokozaki H. Pathobiology. 2004;71(4):176-84.
Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis.
7. Werner SR, Lee PA, DeCamp MW, Crowell DN, Randall SK, Crowell PL. Cancer Lett. 2003 Dec 30;202(2):201-11.
Enhanced cell cycle progression and down regulation of p21(Cip1/Waf1) by PRL tyrosine phosphatases.
6. Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, Lengauer C, Velculescu VE, Kinzler KW, Vogelstein B. Clin Cancer Res. 2003 Nov 15;9(15):5607-15
PRL-3 expression in metastatic cancers.
5. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E, Hong W. Cancer Res. 2003 Jun 1;63(11):2716-22
PRL-3 and PRL-1 promote cell migration, invasion, and metastasis.
4. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. Science. 2001 Nov 9;294(5545):1343-6.
Phosphatase associated with metastasis of colorectal cancer.
3. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M, Acton S, Jeyaseelan R, Kadambi V, Vlahos CJ. Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8.
Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling.
2. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ. J Biol Chem. 2000 Jul 14; 275(28):21444-52.
Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome.
1. Zeng Q, Hong W, Tan YH. Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7.
Mouse PRL-2 and PRL-3, two potentially prenylated protein tyrosine phosphatases homologous to PRL-1.
